BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37808682)

  • 41. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oncolytic Viruses and the Immune System: The Dynamic Duo.
    Lemos de Matos A; Franco LS; McFadden G
    Mol Ther Methods Clin Dev; 2020 Jun; 17():349-358. PubMed ID: 32071927
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 44. YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment.
    Yang X; Lam W; Jiang Z; Guan F; Han X; Hu R; Cai W; Cheng W; Liu SH; Cheng P; Cai Y; Rattray NJW; Johnson CH; Chen L; Cheng YC
    Sci Rep; 2021 Jun; 11(1):13482. PubMed ID: 34188068
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
    Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
    Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Small molecule AZD4635 inhibitor of A
    Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Liu W; Dai E; Liu Z; Ma C; Guo ZS; Bartlett DL
    Mol Ther Oncolytics; 2020 Jun; 17():350-360. PubMed ID: 32405533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oncolytic vaccinia virus acts synergistically with anti-PD-L1 antibody to enhance the killing of colon cancer cells by CD8
    Wu R; Tong S; Yin J; Zhu Z; Mao Z; Xu L
    Pathol Res Pract; 2023 Jul; 247():154535. PubMed ID: 37257241
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment.
    Habanjar O; Bingula R; Decombat C; Diab-Assaf M; Caldefie-Chezet F; Delort L
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835413
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.
    Feola S; Capasso C; Fusciello M; Martins B; Tähtinen S; Medeot M; Carpi S; Frascaro F; Ylosmäki E; Peltonen K; Pastore L; Cerullo V
    Oncoimmunology; 2018; 7(8):e1457596. PubMed ID: 30221051
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using
    Liechtenstein T; Perez-Janices N; Blanco-Luquin I; Goyvaerts C; Schwarze J; Dufait I; Lanna A; Ridder M; Guerrero-Setas D; Breckpot K; Escors D
    Oncoimmunology; 2014; 3(7):e945378. PubMed ID: 25954597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8
    LaPorte KM; Hernandez R; Santos Savio A; Malek TR
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37270181
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cowpea Mosaic Virus Promotes Anti-Tumor Activity and Immune Memory in a Mouse Ovarian Tumor Model.
    Wang C; Fiering SN; Steinmetz NF
    Adv Ther (Weinh); 2019 May; 2(5):. PubMed ID: 33969181
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.